Carotid intima media thickness is related positively to plasma pre ß-high density lipoproteins in non-diabetic subjects.

BACKGROUND Lipid-poor or lipid-free high density lipoprotein (HDL) particles, designated pre ß-HDL, stimulate removal of cell-derived cholesterol to the extracellular compartment, which is an initial step in the reverse cholesterol transport pathway. Pre ß-HDL levels may be elevated in subjects with established cardiovascular disease. We determined the relationship of carotid intima media thickness (IMT), a marker of subclinical atherosclerosis, with pre ß-HDL in subjects without clinically manifest cardiovascular disease. METHODS IMT and plasma pre ß-HDL, assayed by crossed immuno-electrophoresis, were determined in 70 non-diabetic subjects (aged 56±9 years; non-smokers only; 27 women). RESULTS IMT was correlated positively with pre ß-HDL, both expressed as plasma apolipoprotein (apo) A-I concentration (r=0.271, p=0.023) and as% of apo A-I (r=0.341, p=0.004). In contrast, IMT was correlated inversely with HDL cholesterol (r=-0.253, p=0.035). IMT was also related positively to pre ß-HDL after adjustment for age, sex, systolic blood pressure (in apoA-I concentration, ß=0.203, p=0.043; in% of plasma apoA-I, ß=0.235, p=0.023). IMT remained associated with pre ß-HDL after additional adjustment for either body mass index, plasma glucose, cholesterol, triglycerides, HDL cholesterol, apoA-I and apoB. CONCLUSION Subclinical atherosclerosis may relate to higher plasma pre ß-HDL independently of apoA-I and HDL cholesterol levels.

[1]  T. Egashira,et al.  Association of coronary heart disease with pre-beta-HDL concentrations in Japanese men. , 2004, Clinical chemistry.

[2]  C. Fielding,et al.  Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. , 1988, Biochemistry.

[3]  T. Forte,et al.  Cholesteryl ester transfer protein and hepatic lipase activity promote shedding of apo A-I from HDL and subsequent formation of discoidal HDL. , 1992, Biochimica et biophysica acta.

[4]  S. Eisenberg,et al.  High density lipoprotein metabolism. , 1984, Journal of lipid research.

[5]  A. Tall,et al.  Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. , 1999, The Journal of clinical investigation.

[6]  A. van Tol,et al.  Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[7]  A. Hofman,et al.  Genetic Variation at the Phospholipid Transfer Protein Locus Affects Its Activity and High-Density Lipoprotein Size and Is a Novel Marker of Cardiovascular Disease Susceptibility , 2010, Circulation.

[8]  A. Tol Phospholipid transfer protein. , 2002 .

[9]  I. Godsland Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. , 2001, Fertility and sterility.

[10]  M. Taskinen,et al.  Decreased High-Density Lipoprotein (HDL) Particle Size, Pre&bgr;-, and Large HDL Subspecies Concentration in Finnish Low-HDL Families: Relationship With Intima-Media Thickness , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[11]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[12]  T. Miida,et al.  Pre beta 1-high-density lipoprotein increases in coronary artery disease. , 1996, Clinical chemistry.

[13]  B. Wolffenbuttel,et al.  Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. , 2008, Atherosclerosis.

[14]  S. Peters,et al.  Attenuation of Rate of Change in Carotid Intima-Media Thickness by Lipid-Modifying Drugs , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[15]  E. Schaefer,et al.  Distribution of ApoA-I–Containing HDL Subpopulations in Patients With Coronary Heart Disease , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Inder Singh,et al.  High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.

[17]  B. Wolffenbuttel,et al.  Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. , 2011, Cardiovascular therapeutics.

[18]  P. Barter,et al.  Formation and Metabolism of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  R. Dullaart,et al.  Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins , 2003, European journal of clinical investigation.

[20]  P. Duchateau,et al.  Prebeta-1 HDL in plasma of normolipidemic individuals: influences of plasma lipoproteins, age, and gender. , 1998, Journal of lipid research.

[21]  L. Cupples,et al.  High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[22]  G. Franceschini,et al.  Depletion of Pre-β-high Density Lipoprotein by Human Chymase Impairs ATP-binding Cassette Transporter A1- but Not Scavenger Receptor Class B Type I-mediated Lipid Efflux to High Density Lipoprotein* , 2004, Journal of Biological Chemistry.

[23]  B. Dahlbäck,et al.  Apolipoprotein M predicts pre‐β‐HDL formation: studies in type 2 diabetic and nondiabetic subjects , 2009, Journal of internal medicine.

[24]  Serkalem Demissie,et al.  Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[25]  A. Smit,et al.  Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus , 2006, Diabetologia.

[26]  M. Seishima,et al.  Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. , 2005, Clinical chemistry.

[27]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[28]  Børge G Nordestgaard,et al.  High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. , 2010, Clinical chemistry.

[29]  C. Fielding,et al.  Prebeta-migrating high density lipoprotein: quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer. , 1987, Journal of lipid research.

[30]  A. Groen,et al.  Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment , 2005, Diabetologia.

[31]  F. Grosveld,et al.  Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[32]  R H Selzer,et al.  Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. , 1994, Atherosclerosis.

[33]  Gerard E. Dallal,et al.  Change in &agr;1 HDL Concentration Predicts Progression in Coronary Artery Stenosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[34]  P. Barter,et al.  Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. , 1998, Journal of lipid research.

[35]  G. Dallinga-Thie,et al.  Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein. , 2009, Biochimica et biophysica acta.

[36]  J. Pais de Barros,et al.  Worsening of Diet-Induced Atherosclerosis in a New Model of Transgenic Rabbit Expressing the Human Plasma Phospholipid Transfer Protein , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[37]  T. van Gent,et al.  Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200166-JLR200 , 2002, Journal of Lipid Research.

[38]  R. Krauss,et al.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.

[39]  A. Tall,et al.  Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency , 2001, Nature Medicine.

[40]  P. Barter,et al.  Remodelling of high density lipoproteins by plasma factors. , 1999, Atherosclerosis.

[41]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[42]  E. Schaefer,et al.  Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. , 2007, The American journal of cardiology.

[43]  Christian Zellner,et al.  Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. , 2011, The American journal of cardiology.